(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T

(177)Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundschuh, Ralph A., Pfob, Christian H., Wienand, Georgine, Dierks, Alexander, Kircher, Malte, Lapa, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988218/
https://www.ncbi.nlm.nih.gov/pubmed/36692961
http://dx.doi.org/10.1097/RLU.0000000000004573
Descripción
Sumario:(177)Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old man with metastastic castrate-resistant prostate cancer undergoing (177)Lu-PSMA-I&T treatment. After initial partial response to radioligand therapy, another 2 treatment cycles resulted in a rising serum PSA level that could be correlated with increasingly PSMA-positive as well as a new bone lesion. Consequently, the patient was changed to (177)Lu-rhPSMA-10.1 treatment on a compassionate use basis achieving a renewed tumor response.

Ejemplares similares